Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals Inc (NYSE: AMRX) delivers essential medicines through its focus on affordable generics and specialty pharmaceuticals. This news hub provides investors and healthcare professionals with timely updates on regulatory developments, strategic partnerships, and operational milestones.
Our curated collection features official press releases and verified news coverage spanning key business segments. Track updates on generic drug approvals, manufacturing expansions, and AvKARE distribution network enhancements. Access filings related to FDA submissions, intellectual property developments, and corporate governance matters.
Discover comprehensive coverage of earnings announcements, research collaborations, and therapeutic area advancements. The resource serves as an objective reference for monitoring AMRX's role in improving medication accessibility while maintaining quality standards across global markets.
Bookmark this page for streamlined access to Amneal's latest developments in generic pharmaceuticals and complex drug formulations. Regularly updated content supports informed analysis of this NYSE-listed company's market position and industry contributions.
Amneal Pharmaceuticals (NASDAQ: AMRX) reported strong Q2 2025 financial results with net revenue of $725 million, up 3% year-over-year, and net income of $22 million. The company achieved notable growth with Adjusted EBITDA of $184 million, a 13% increase, and adjusted diluted EPS of $0.25, up 56% from Q2 2024.
Key highlights include a 23% increase in Specialty net revenue driven by products like CREXONT®, RYTARY®, and UNITHROID®. The company successfully completed a $2.7 billion debt refinancing, extending maturities to 2032 and reducing interest costs. Based on strong performance, Amneal raised its full year 2025 guidance, increasing adjusted EBITDA targets to $665-685 million and adjusted EPS to $0.70-0.75.
[ "Net revenue increased 3% to $725 million year-over-year", "Specialty segment revenue grew 23% driven by key branded products", "Adjusted EBITDA increased 13% to $184 million", "Adjusted diluted EPS grew 56% to $0.25", "Successfully completed $2.7B debt refinancing with extended maturities to 2032", "Raised full year 2025 guidance for adjusted EBITDA and EPS", "Operating cash flow guidance increased to $275-305 million" ]Amneal Pharmaceuticals (NASDAQ: AMRX) has announced a major refinancing initiative through its subsidiary, Amneal Pharmaceuticals LLC. The company plans to secure $1.8 billion in new seven-year term B loans and is offering $750 million in senior secured notes due 2032.
The proceeds will be used to refinance existing term B loans, repay a portion of outstanding ABL facility borrowings, and cover related expenses. The notes will be guaranteed on a senior secured basis and will have first-priority liens on collateral (except ABL priority collateral) and second-priority liens on ABL priority collateral. The completion of these transactions remains subject to market conditions.
The notes will be offered exclusively to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S of the Securities Act.Amneal Pharmaceuticals (NASDAQ: AMRX) has released preliminary Q2 2025 financial results showing strong performance. The company reported net revenue of $720-730 million, up 3% year-over-year, and Adjusted EBITDA of $180-185 million, increasing approximately 13% from Q2 2024.
Key highlights include improved leverage metrics, with gross leverage decreasing to 3.8x from 4.1x and net leverage reducing to 3.7x from 3.9x. The quarter also marked the FDA approval of Brekiya® autoinjector for migraine treatment and strong uptake of CREXONT®. The company expects to meet or exceed its full-year 2025 guidance and plans to submit a BLA for a proposed XOLAIR® biosimilar in Q4 2025.
Amneal Pharmaceuticals (NASDAQ: AMRX), a global biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, before the market opens. The company will host an audio webcast at 8:30 a.m. ET to discuss the results.
Investors can access the webcast through Amneal's Investor Relations website at investors.amneal.com. For those joining via phone, the U.S. dial-in number is 1 (833) 470-1428 with access code 627786. A replay will be available after the call.
Amneal Pharmaceuticals (Nasdaq: AMRX) announced positive topline results from a Phase 3 clinical trial for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences. The study met its primary and secondary endpoints, demonstrating therapeutic equivalence and comparable safety to XOLAIR® in 400 patients with Chronic Idiopathic/Spontaneous Urticaria.
The trial evaluated doses of 150mg or 300mg administered subcutaneously every four weeks over 24 weeks. Amneal holds exclusive U.S. commercialization rights, with a Biologics License Application (BLA) planned for Q4 2025. The biosimilar targets the $3.9 billion U.S. omalizumab market and is part of Amneal's strategy to launch six biosimilars across eight product presentations by 2027.
Amneal Pharmaceuticals (NASDAQ: AMRX) has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 5 at 9:20 AM ET and participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10 at 10:40 AM ET.
Co-CEO and President Chirag Patel and CFO Tasos Konidaris will represent Amneal at both events. Investors can access live webcasts through the company's investor relations website, with replay options available after the events.
Amneal Pharmaceuticals (NASDAQ: AMRX) has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector for acute treatment of migraine and cluster headaches in adults. The product will be available in H2 2025.
Brekiya represents a significant advancement as it allows patients to self-administer the same DHE medication used in hospitals through a convenient, ready-to-use autoinjector that requires no refrigeration, assembly, or priming. The device delivers one subcutaneous dose into the thigh and may provide sustained pain relief for up to 24-72 hours.
This innovation addresses a substantial market, with 39 million Americans suffering from migraines and up to 1 million affected by cluster headaches. Headaches represent the fourth most common reason for emergency department visits, accounting for 3% of all ER visits in the US.
Amneal Pharmaceuticals (NASDAQ: AMRX) and Apiject Systems have announced a strategic collaboration to expand domestic production of Apiject's Blow-Fill-Seal (BFS) injectable platform at Amneal's Brookhaven, NY facility. The partnership will create approximately 200 new jobs and enable production capacity of 250-300 million units annually, scalable to over 400 million units.
The collaboration integrates BFS manufacturing with precision injection molding of pen-style needle hubs, creating sterile, single-dose, prefilled injectors. This technology, partially developed through a $180 million investment from HHS, offers a more efficient alternative to traditional glass vials and syringes. The project will enhance Amneal's U.S. manufacturing capabilities for sterile drug dosage forms, including injectables, ophthalmics, and inhalation products.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
